CLEVELAND – Attendees who stuck around for the end of the Cleveland Clinic Innovation Summit were rewarded with what has become the signature event for the meeting: the Top 10 Medical Innovations for the coming year. Read More
Despite posting an estimate-beating 70 percent rise in third quarter net profit, slowing sales growth for Gilead Sciences Inc.'s hepatitis C virus (HCV) drugs attributed to payer restrictions weighed on company shares (NASDAQ:GILD), which slid $2.83, to close at $108.13 on Wednesday. Read More
Science or technology that fails to measure up and weak leadership make for sure-fire deal-killers in the venture capital (VC) world, but there's more to it, said Jay Lichter, managing partner with Avalon Ventures in San Diego. Read More
DUBLIN – Turnstone Biologics Inc. raised $11.3 million in a series A round to take forward a novel oncolytic virus platform, based on a modified rhabdovirus strain that has strong immune-boosting properties as well as systemic oncolytic activity. Read More
A break in the budget stalemate could position the FDA and NIH for more funding this year and next, but the details have yet to be played out. Read More
Look out, big pharma. The first generation of scientists who came of age during the genomics revolution is transitioning from the classroom to the boardroom, and they're seeking to shake up the industry. Read More
Cel-Sci Corp., of Vienna, Va., said it closed a best efforts offering of 17.2 million shares of common stock and 17.2 million warrants to purchase shares of common stock, sold at a combined price of 67 cents per unit. Read More
Ipsen SA, of Paris, and Telesta Therapeutics Inc. (formerly Bioniche Life Sciences Inc.), of Montreal, inked an exclusive licensing agreement giving Ipsen the right to develop and commercialize MCNA1 to treat high-risk nonmuscle-invasive bladder cancer (NMIBC) outside the U.S., where Telesta is establishing commercial operations, as well as Canada, South Africa, Mexico, South Korea and Japan. Read More
Macrocure Ltd., of Petach Tikva, Israel, said results of a phase III trial of Curexcell in the treatment of diabetic foot ulcers (DFUs) did not meet its primary endpoint, failing to show a statistically significant proportion of subjects with complete closure at 16 weeks and sustained complete closure for four additional weeks. Read More
